AbbVie Inc (ABBV)
170.75
-1.99
(-1.15%)
USD |
NYSE |
Jun 25, 16:00
171.25
+0.50
(+0.29%)
After-Hours: 20:00
AbbVie Research and Development Expense (Annual): 7.675B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.675B |
| December 31, 2022 | 6.51B |
| December 31, 2021 | 6.922B |
| December 31, 2020 | 6.379B |
| December 31, 2019 | 6.407B |
| December 31, 2018 | 10.33B |
| December 31, 2017 | 5.007B |
| December 31, 2016 | 4.385B |
| Date | Value |
|---|---|
| December 31, 2015 | 4.285B |
| December 31, 2014 | 3.297B |
| December 31, 2013 | 2.855B |
| December 31, 2012 | 2.778B |
| December 31, 2011 | 2.618B |
| December 31, 2010 | 2.495B |
| December 31, 2009 | 1.707B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
6.379B
Minimum
2020
7.675B
Maximum
2023
6.779B
Average
6.51B
Median
2022
Research and Development Expense (Annual) Benchmarks
| Johnson & Johnson | 15.08B |
| Eli Lilly and Co | 9.313B |
| Pfizer Inc | 10.68B |
| Bristol-Myers Squibb Co | 9.299B |
| Merck & Co Inc | 30.53B |